UK Community Advisory Board (UK-CAB)

UK-CAB41: TB and HIV


09:30 – 09:50 Registration, refreshments and expenses
09:50 – 10:00 Welcome, introductions, UKCAB updates
10:00 – 11:15 TB and HIV: Screening and treatment– Dr Santino Capocci, Royal Free Hospital
11:15 – 11.30 Break
11:30 – 12.15 TB-HIV: Strengthening Community Response. – Gitau Mburu, Int. HIV/AIDS Alliance
12:15 – 12.45 Company pre-meeting on TMC207 – Polly Clayden, HIV i-Base
12:45 – 14:00 Lunch
14:15 – 15:30 Company meeting: Janssen
15.30 – 15.35 Break
15:35 – 16:00 UKCAB London drug survey feedback – Mark Platt
16.00 Close

Background reading

What is TB? – Extracted from the i-Base treatment training for advocates

BHIVA guidelines for the treatment of TB/HIV coinfection 2011:

How TB is treated

Medicines for people with TB – contains 1st line, multi-drug resistant TB and extremely drug resistant TB medicines.  There is also a section on pipeline drugs.

Global TB drug pipeline:

Faster conversion rates with TMC-207 versus placebo plus OBT for the treatment of MDR-TB – study on a new drug with the potential to improve both drug-sensitive and multi-drug resistant TB.

2011 pipeline report: 2nd edition (September 2011) – covers the most recent and exciting developments in HIV, hepatitis and TB research. [PDF download, 1MB]

TB in our Lives – A detailed guide by Treatment Action Campaign in South Africa, with emphasis on coinfection with HIV.  Activists wrote the guide about how TB attacks the body, how it is treated and the things they can do to help fight TB in their communities.

They explain things in a way that makes sense and that is not too technical so that readers can go on and explain about TB to others. The guide has information sheets for people living with TB, support groups and clinics. [PDF download]

Other useful links:

Financial support

The UK-CAB receives unrestricted funding from some pharmaceutical companies towards the direct costs of holding four meetings each year. This funding supports the travel and accommodation costs for members to attend from outside London, plus the cost of catering.

The content, programme and agenda for meetings is decided by the UK-CAB steering group in consultation with the wider membership. Funding is unconnected to meeting content.

We believe that manufacturers who currently develop and market medicines have a responsibility to actively engage with advocacy organisations and that HIV positive people and their advocates should be able to directly question manufacturers about the safety and efficacy of their products and proposals for future research.

For a list of companies that support the UK-CAB please see the “about us” page.